The one Australian stock to buy and hold forever in an ASX share portfolio

Buy and hold investing could be your ticket to wealth. Let's see why.

| More on:
A woman presenting company news to investors looks back at the camera and smiles.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

When it comes to building long-term wealth, few strategies are as effective as buy and hold investing. By focusing on high-quality companies and giving them time to grow, investors can take full advantage of the power of compounding.

This approach not only reduces trading costs and taxes but also allows you to ride out the market's ups and downs without the stress of trying to time your buys and sells.

Simply brilliant

The beauty of buy and hold investing lies in its simplicity. Rather than constantly monitoring the market or chasing trends, investors can concentrate on finding fundamentally strong companies with sustainable competitive advantages, solid management teams, and long-term growth potential.

These businesses tend to weather economic downturns better and emerge stronger when conditions improve. Over time, they can provide both capital appreciation and growing income streams through dividends.

A key benefit of this strategy is that it rewards patience. The longer you hold onto quality stocks, the more you allow them to deliver consistent returns. Even small annual gains can compound into significant wealth over decades.

But which Australian stock could be a great long-term option for ASX investors today? Let's take a look at one leading candidate that analysts love.

A top Australian stock to buy and hold

The stock in question is CSL Ltd (ASX: CSL).

There are a large number of brokers that have become extremely bullish on the biotherapeutics company in recent months.

For example, the team at Goldman Sachs has just initiated coverage on the plasma therapies leader with a buy rating and $325.40 price target. It said:

Our Buy recommendation for CSL is driven by (1) Strong growth in the IG market despite the entry of new drugs (anti-FcRn), (2) CSL market share gains in the IG market, Hemophilia, Hereditary Angiodema (HAE) and influenza vaccines, and (3) Gross Margin accretion driven by operational improvements to its cost base. We believe CSL's valuation multiple de-rate is onerous considering the growth outlook, particularly for IG therapies.

Elsewhere, analysts at Bell Potter recently put a buy rating and $345.00 price target on this Australian stock. They said:

We expect CSL will achieve guidance of "annual double-digit earnings growth" over the mid-term driven largely by the legacy plasma business, Behring, particularly its immunoglobulin sales. While CSL's Seqirus and Vifor business units do face near-term headwinds (reduced flu market demand and generic iron competition), these two units combined only contribute less than a third of total earnings. CSL continues to be a high quality, global operator with a multi-year gross margin recovery well underway to drive earnings expansion. The stock is currently trading at a 12m forward PE 27% and 19% below 5- and 10-year averages, respectively.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the 'five best ASX stocks' for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now...

See The 5 Stocks *Returns as of 30 April 2025

Motley Fool contributor James Mickleboro has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Goldman Sachs Group. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Blue Chip Shares

A businessman hugs his computer and smiles.
Blue Chip Shares

3 excellent ASX shares I would buy and hold for the next 10 years

Analysts think these quality companies could be in the buy zone right now.

Read more »

A group of people in suits watch as a man puts his hand up to take the opportunity.
Blue Chip Shares

The ultimate blue chip portfolio: 3 ASX 200 stocks to anchor your investments

Starting your investment journey? Here are three stocks that Goldman Sachs rates very highly.

Read more »

Happy shareholders clap and smile as they listen to a company earnings report.
Blue Chip Shares

3 quality ASX stocks that could lead the next market rebound

These stocks are highly rated by analysts for a reason. Here's what you need to know.

Read more »

Happy woman in front of padlocks
Blue Chip Shares

3 of the best ASX 200 blue chip shares to buy now

Analysts think these quality stocks would be top picks right now.

Read more »

A young man punches the air in delight as he reacts to great news on his mobile phone.
Blue Chip Shares

3 quality ASX shares to buy before the market rebounds

These shares are highly rated by analysts. Let's see why they are bullish.

Read more »

Male building supervisor stands and smiles with his arms crossed at a building site with workers behind him.
Blue Chip Shares

3 reasons to buy this 'high-quality' $14 billion ASX 200 stock today

A leading expert forecasts a big potential turnaround for this beaten down ASX 200 stock.

Read more »

Three happy office workers cheer as they read about good financial news on a laptop.
Blue Chip Shares

3 leading ASX 200 blue chip shares to buy after the market selloff

Let's see which shares analysts are recommending to clients.

Read more »

Three business people join hands in strength and unity
Blue Chip Shares

3 unstoppable ASX 200 stocks to buy and hold forever

Analysts think these blue chips could be strong buys.

Read more »